Investor Hub
Latest quarterly earnings
Latest investor presentation
Annual report
Latest publications
Pipeline
NASDAQ:NVAX
NASDAQ:NVAX
Latest quarterly earnings
Latest investor presentation
Annual report
Latest publications
Pipeline
Latest press releasesEvents & presentationsReports & financialsSEC filingsStock details & analyst coverage
Press releases & statements
Apr 18, 2026
Statement
COVID-19,Corporate and finance,Partnerships
Nuvaxovid™ COVID-19 Vaccine Showed Better Tolerability than mNEXSPIKE in Head-to-head Sanofi-led Phase 4 Study
Mar 30, 2026
Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
Latest press releasesEvents & presentationsReports & financialsSEC filingsStock details & analyst coverage
Press releases & statements
Apr 18, 2026
Statement
COVID-19,Corporate and finance,Partnerships
Nuvaxovid™ COVID-19 Vaccine Showed Better Tolerability than mNEXSPIKE in Head-to-head Sanofi-led Phase 4 Study
Mar 30, 2026
Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
Corporate governance
IR
contact
contact
Phone
(240) 268-2022
Email
Get notifications for investor updates
Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings and more.
Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.
